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Abstract
Identifying gene regulatory elements and their target genes in vertebrates remains a significant challenge. It is now
recognized that transcriptional regulatory sequences are critical in orchestrating dynamic controls of tissue-specific gene
expression during vertebrate development and in adult tissues, and that these elements can be positioned at great
distances in relation to the promoters of the genes they control. While significant progress has been made in mapping DNA
binding regions by combining chromatin immunoprecipitation and next generation sequencing, functional validation
remains a limiting step in improving our ability to correlate in silico predictions with biological function. We recently
developed a computational method that synergistically combines genome-wide gene-expression profiling, vertebrate
genome comparisons, and transcription factor binding-site analysis to predict tissue-specific enhancers in the human
genome. We applied this method to 270 genes highly expressed in skeletal muscle and predicted 190 putative cis-
regulatory modules. Furthermore, we optimized Tol2 transgenic constructs in Xenopus laevis to interrogate 20 of these
elements for their ability to function as skeletal muscle-specific transcriptional enhancers during embryonic development.
We found 45% of these elements expressed only in the fast muscle fibers that are oriented in highly organized chevrons in
the Xenopus laevis tadpole. Transcription factor binding site analysis identified .2 Mef2/MyoD sites within,200 bp regions
in 6 of the validated enhancers, and systematic mutagenesis of these sites revealed that they are critical for the enhancer
function. The data described herein introduces a new reporter system suitable for interrogating tissue-specific cis-regulatory
elements which allows monitoring of enhancer activity in real time, throughout early stages of embryonic development, in
Xenopus.
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Introduction
Many vertebrate genes exhibit highly intricate temporal and
spatial expression patterns that span multiple stages of embryonic
development, and specific embryonic or adult cell types. Several
also respond to environmental and metabolic stimuli [1,2]. While
automated global gene expression methods, such as microarrays or
tissue arrays have greatly expanded our view of the ‘transcriptome’
or where and when genes are expressed, we have yet to improve
our ability to determine the transcriptional regulatory DNA
sequences that are responsible for turning genes on and off,
therefore understanding the regulatory mechanisms that drive
expression of genes during development or in specific tissues
remains one of the central problems in genome biology.
While transcription is mediated in part by promoters and
promoter proximal elements that coordinate the site of initiation
and contribute to the levels of transcription, distal cis-regulatory
elements such as enhancers, insulators, locus control regions, and
silencing elements control the stage and region-specificity of
expression. These sequences are frequently positioned at great
distances from the promoters of the genes they control. In
addition, recent evidence suggests that exons can also function as
transcriptional regulatory sequences of near-by genes [3]. Since
regulatory elements can be present anywhere in the vicinity or
within an open reading frame, and their sequence signatures are
currently indistinguishable from non-functional DNA, only modest
progress has been made in identifying distal enhancers in a high
throughput manner, leaving most of the noncoding regions of
mammalian genomes unannotated. Currently, the majority of the
non-repetitive, noncoding genome of any sequenced vertebrate
organism is of unknown function, through this ‘junk’ DNA may
comprise a large fraction of the genome (estimated to be ,50% of
the genome in humans). However, increasing evidence suggests
that a significant proportion of the noncoding sequences, possibly
up to 80% (encode papers) contain regulatory elements responsible
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for the elaborate expression programs in the diverse cell types of
the vertebrate body.
While comparative sequence analysis has emerged as an
efficient tool for prioritizing noncoding sequences likely to function
as transcriptional regulatory elements in vivo, conservation alone
has failed to advance our ability to predict the tissue-specificity of a
regulatory element, de novo. For example, while searching for a
bone enhancer in a 52 kb human deletion known to caused Van
Buchem disease and harboring 17 human to mouse conserved
noncoding sequences (.100 bp; .70% sequence identity, only
one of the seven tested sequences displayed enhancer activity, in
the UMR-106 osteosarcoma cell line [4]. Furthermore, this
element had to be validated in vivo, in transgenic mice to confirm
its tissue specificity in the mouse skeleton [5].
During the last decade, we and others have developed
computational and experimental methods that would help address
several unresolved questions: Where are distal cis-regulatory
sequences located in vertebrate genomes? Are they likely to
control single or multiple transcripts? Do they activate expression
in single or multiple cell types? Is there a ‘code’ associated with cell
type specific distal enhancers? The ENCODE project has already
initiated work that addresses some of these questions and recent
valuable insights have been obtained that describe new chromatin
patterns at transcription factor binding sites [6], chromatin
modification patterns around promoters that may influence tissue
specificity [7] as well as DNA methylation profiles linked to
specific regulatory elements [8]. While all these insightful
approaches have greatly expanded our view of the human
genome’s regulatory landscape, two important aspects have not
been addressed by any ENCODE project, mainly can we predict
and annotate tissue specific enhancers, de novo? Most importantly it
remains to be determined how the data derived from cell lines
translates to the full organismal level. Since our existing knowledge
of distal regulatory elements is very limited, for significant progress
to occur, we primarily need to improve our available methods for
testing and characterizing transcriptional regulatory elements,
in vivo, to expand our repertoire of ‘validated’ tissue specific
enhancers, which could subsequently be used to further our
understanding of the sequence signatures or ‘regulatory code’ of
vertebrate genome.
Using a transposon mediated transgenesis method originally
developed in Zebrafish [9] and more recently optimized in both
Xenopus laevis and tropicalis [9–11] here we describe a general
purpose transgenesis construct that can be used in transient
transgenic frogs to interrogate potential transcriptional regulatory
sequences for their ability to function as tissue-specific transcrip-
tional enhancers during embryonic development. This procedure
is based on Tol2 transposable elements isolated from the fish
Orzyias latipes (Medaka), where a circular plasmid containing the
transgenic construct flanked by Tol2 arms is injected into fertilized
eggs along with the Tol2 transposase RNA. In building a suitable
reporter system amenable to high throughput validation of distal
cis-regulatory elements we aimed to construct a vector that would
incorporate: (1) a minimal promoter that is either ‘off’ in the
absence of a strong transcriptional enhancer, or is ‘on’ in a highly
restrictive manner, for example it only expresses reproducibly in a
subset of cell types and can be used as a positive control for
transgensis; and (2) a fluorescent reporter gene that is bright, stable
and folds relatively quickly to allow us to monitor enhancer activity
in real time during early stages of development.
We also wanted our system to yield high numbers of transgenic
embryos that express robust levels of the transgenic protein in a
reproducible pattern to allow us to reliably analyze first generation
transgenic embryos (G0) without having to pass the transgenes
through the germline. Here we report that gamma-crystallin (c-cry)
represents an ideal minimal promoter for interrogating transcrip-
tional cis-regulatory elements in Tol2-mediated transgenic Xenopus
laevis embryos. The expression of the red fluorescent protein
mKate2 in the lens beyond embryonic stage 35 allows us to assess
transgenic efficiency in the absence of enhancer activity. Using
three known tissue specific enhancers (one kidney and two skeletal
muscle enhancers) we optimized transgenic efficiency to obtain up
to 93% transgenic embryos among the surviving tadpoles.
Furthermore, we proceeded to correlate tissue specific expression
of candidate muscle enhancer elements predicted using a
computational methods previously described (Pennacchio et al.
2007), and found 55% (11/20) of the tested elements to exhibit
enhancer activity, where 45% (9/11) specifically drove expression
in the predicted tissue. This simple and efficient technique
represents a powerful new tool for high-throughput transgenic
analysis of candidate cis-regulatory elements. Germ line transmis-
sion of Tol2 X. tropicalis transgenic embryos generated using
validated enhancer elements will facilitate the generation of tissue-
specific reporter transgenic lines that can be used in future genetic
studies in the diploid X. tropicalis.
One great advantage of using Xenopus over the gold standard
set by the mouse is the ability to view gene expression during early
embryonic development in real time. Because of in utero
development, transient transgenic expression in mice can only
be characterized at specific time points during development. To be
able to capture the transgene expression, one needs to know when
and where the controlled transcript is expressed in order to predict
the developmental window a putative cis-regulatory element is
likely to function. Since gene expression for most genes is highly
dynamic, in the absence of such detailed transcriptional informa-
tion, cis-regulatory predictions focusing on characterization at a
single time point are likely to miss a plethora of elements that act
earlier or later in development. Pennacchio et al. examined over
2000 conserved noncoding elements in transgenic mice at E11.5
and found ,30% of these elements to generate reproducible
expression patterns [12], some of which may have been missed due
to the selected time point. The transgenic approach describe here
represents an alternative method for examining the regulatory
landscape in vertebrates and is likely to facilitate the discovery of
novel DNA sequences with transcriptional regulatory potential.
Results
Tol2 Transgenesis Provides High Survival and High
Transgenic Efficiency in G0 Embryos
Genetically encoded fluorescent proteins have been widely used
as transgenic reporters and have been primarily optimized for
mammalian in vitro and in vivo applications; among them green
fluorescent protein (GFP) has been most widely used. One of the
great challenges associated with GFP in vivo imaging in embryos
involves minimizing the effects of background fluorescence, or
autofluorescence. Autofluorescence is a fluorescent signal derived
from substances other than the fluorophore of interest, and
inherently animal tissues tend to display high autofluorescence
levels in the visible wavelength range. While autofluorescence can
be chemically quenched in fixed tissues, this becomes a challenge
when imaging live tissues that have low transgenic expression
levels. Recent reports have examined a family of far-red
fluorescent proteins and have shown that both in tissue culture
and in animals, these fluorescent proteins have high fluorescence
resonance energy transfer efficiency (brighter); they also take
advantage of the reduced light scattering associated with far-red
illumination (allowing deep tissue imaging), and reduced excitation
Transgenic Xenopus
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of yolk and other autofluorescent proteins, suggesting that they are
well suited for real-time in vivo imaging [13]. We examined several
far-red proteins for their ability to generate a strong signal in live
embryos. We injected 1 mg of synthetic Cherry, Katushka,
membrane RFP (mRFP), Orange, Strawberry and Tomato
mRNAs into fertilized embryos and imaged them 20 hours post
injection (Fig. 1A) (stages 18–20). We found Cherry and Katushka
to have the highest fluorescence intensity, followed by Strawberry,
Tomato and membrane RFP which were moderately bright and
lastly Orange which had the weakest signal (Fig. 1A).
Using the ubiquitous human cytomegalovirus (CMV) and EF1A
promoters driving Katushka red fluorescent protein we compared
transgenic efficiency using two previously described transgenic
methods: restriction enzyme mediated integration (REMI) and
transposon mediated transgenesis. Based on previously reported
transgenic success, we chose to examine two different transposon
systems: PiggyBAC [14] and Tol2 [9,10,15] to determine which
transgenic method yields the highest transgenic efficiency. We
built plasmids that carried the CMV-Katushka or EF1A-Katushka
cassettes flanked by PiggyBAC or Tol2 arms [9,10,14,16]. These
promoters have been widely used in a variety of vertebrate species
and their activity has already been characterized by REMI and
Sce-I mediated transgenesis in X. laevis and X. tropicalis [17] hence
they provide a robust assay for assessing the efficacy of these
methods. All experiments were performed on groups of 250
embryos per experiment (N= 4), and with equal amounts of DNA
or DNA+RNA ratios. Nuclear transfer was carried out as
previously described [18,19]. For the transposon mediated
transgenesis 200 pg of plasmid DNA was co-injected with
200 pg of freshly synthesized transposon mRNA at the 1-cell
stage. After the injection, Katushka expression in the embryos was
examined daily using an epifluorescence microscope up to stage
45, and scoring was carried out primarily between stages 35 and
40. For each experiment we tabulated the number of surviving
tadpoles, the number of transgenic embryos, and the level of
transgenic expression. We classified the transgenic expression
intensity in three categories: ubiquitous (expression throughout the
embryo), low mosaic (a small subset of the embryo) or high mosaic
(spotty expression but covering more than 50% of the embryo).
Of the 250 injected embryos, we observed the lowest survival
rate for the nuclear transfer method, averaging ,30% survival
(75/250). In contrast, both transposon mediated transgenic
procedures had robust survival rates of up to ,88% (220/250)
(Fig. 1B; Sup. Table 1). Tol2 transgenesis outperformed the other
two methods with transgenic rates as high as 90% compared to
34% for REMI, but expression intensity was variable and mosaic
where 50% embryos had ubiquitous expression, 30% had high
chimeric expression and 20% had low chimeric expression
(Fig. 1C; Table S1). PiggyBAC generated the least reliable results
in our hands. While the viability and transgenic rate were higher
than REMI, the majority of the transgenic embryos had very low
expression level (334/372) and the transgene was expressed at
random in subsets of cells. With both PiggyBAC and Tol2, we also
observed low level random transgenic expression in DNA
injections without transposase RNA. Despite the high sensitivity
of the nuclear transfer method, the high morbidity rate suggested
that the Tol2 transgenic method has a higher potential for
evolving into a reliable approach for validating and characterizing
cis-regulatory elements in a transient transgenic assay. All
subsequent transgenic experiments were carried out using Tol2-
mediated transgenesis.
Keratin 8 and c-crystallin Promoters Drive Robust
Enhancer-specific Expression in Xenopus
An ideal minimal promoter suitable for interrogating transcrip-
tional enhancers would be either silent or ‘on’ in a highly specific
subset of cells, yet would show consistent activation of tissue-
specific expression at high levels when paired with an enhancer
element. Several minimal promoters have been successfully used in
mouse transient or stable transgenic lines, including Hsp68 and b-
globin. Among .1200 putative enhancers tested using the Hsp68
promoter in mice, a significant fraction of the ,600 elements with
enhancer activity had neuronal specific patterns, suggesting that
Hsp68 may be prone to non-specific activation of transgenes in the
nervous system [12] (enhancer.lbl.gov). The b-globin promoter has
been shown to be less susceptible to non-specific activation,
however, we find this promoter to be highly specific but less
sensitive and provides weaker expression level, in transgenic mice
[5]. In zebrafish the keratin 8 (Krt8) promoter has been successfully
used for both enhancer validation as well as for enhancer trapping
[20,21], and gamma-crystallin (c-cry) has been frequently used in
Xenopus transgenic assays as a positive control [22]. The Krt8
promoter drives expression on the surface layer of stratified
Figure 1. Comparing fluorescent reporter expression and transgenic efficiency in transgenic embryos generated by nuclear
transfer, PiggyBAC or Tol2 transgenesis. Six red fluorescent proteins were examined for bright expression in Xenopus oocytes (A). Using the
brightest red fluorescent gene, Katushka, constructs with a ubiquitous promoter (CMV) were examined by three methods: nuclear transfer, PiggyBAC
transposition and Tol2 transposition. 250 embryos were injected in four independent experiments using CMV-Katushka constructs, and the number
of surviving and transgenic embryos were assessed (Table S1); significantly fewer transgenic embryos (p-value ,0.005) were generated by nuclear
transfer and PiggyBAC, where large numbers of the surviving Tol2 embryos were transgenic (B). Tol2 transgenics were found to give the brightest
and most reliable expression in Xenopus (C).
doi:10.1371/journal.pone.0068548.g001
Transgenic Xenopus
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epithelial tissues primarily in the skin epidermis while the c-cry
promoter is specific for the lens.
As initial test enhancers, we selected the Irx3 kidney enhancer
(KE) that has been previously characterized in Xenopus [23] along
with two rodent-derived skeletal muscle enhancers (ME) [24,25].
The kidney enhancer (KE) is 2 kilobases (kb) in length, is
positioned ,90 K upstream of the Irx3 transcript and is highly
conserved from man to fish (Fig. 2A). The dystrophin ME
enhancer is 529 basepairs (bp) in length and positioned within the
first intron of the dystrophin mouse gene. It was originally found to
activate transcription in myogenic cells in both cell lines and
transgenic mice [25]. The Myosin light chain 1/3 ME enhancer is
955 bp in length, is positioned downstream of the rat Myosin light
chain 1/3 gene (Myl1) and has been validated in primary muscle
cells derived from both mice and rats [24]. Both MEs are highly
conserved from human to mouse (Fig. 2A), but not conserved in
chicken, frog nor fish as evaluated by sequence alignments in their
respective genomic loci. The KE and ME enhancers were cloned
in front of the b-globin, c-cry, Hsp68, Irx3 and Krt8 promoters in the
T2 vector and were tested in X. laevis embryos (Fig. 2B).
Transgenic expression was evaluated in live embryos between
embryonic stages 30–45 monitoring enhancer- and promoter-
specific target tissues (Fig. 2C). The b-globin and Irx3 promoter
only constructs gave very little or no signal, the c-cry promoter
showed high signal with 100% eye specificity, the Krt8 promoter
displayed varying degrees of low level skin expression, and the
Hsp68 construct exhibited high frequency, high intensity, random
expression patterns (Fig. 2D; Table 1). In combination with KE,
the c-cry and Irx3 promoters generated the most specific expression
patterns (Fig. 2E), where c-cry continued to show 100% target
specificity for both promoter and/or enhancer expression, and the
Irx3 construct had ,10% random non-specific expression. The
Krt8 had the brightest kidney expression but the relative frequency
of transgenic embryos with kidney expression was low (24%) and a
large number of transgenic embryos had high, random expression
patterns (16%). The Hsp68 construct continued to display the
largest number of very bright, non-enhancer specific expression
with .50% of transgenic embryos expressing in eye, skin, muscle
or tissues other than kidney (Fig. 2E; Table 1). The b-globin
promoter was the least responsive to the KE (27% transgenesis),
and among the transgenics the expression level was very low and
relatively non-specific (Fig. 2E; Table 1).
The dystrophin ME was a relatively weak enhancer, and only
the Krt8 promoter was robustly activated while all other promoters
showed transgene expression in a few muscle cells (Fig. 2F). The
Myl1 ME was a much stronger enhancer, the c-cry and Krt8
promoters gave the highest rate of transgenic embryos (93%), high
specificity (96% and 89%) and very bright expression, while the b-
globin and Irx3 had the lowest transgenic rates (70% and 50%) and
very weak transgenic expression (Fig. 2G). While the strong ME
enhancer displayed the lowest non-specific expression in all
constructs, the c-cry and Krt8 consistently exhibited the strongest
expression intensity, with c-cry outperforming Krt8 in tissue-
specificity. c-cry in combination with all 3 enhancers had 100%
tissue-specificity and was shielded from position effect. Based on
this assessment we determined that c-cry may be the most suitable
promoter for interrogating cis-regulatory elements in Tol2-
transgenic Xenopus due to its high specificity of enhancer activation,
built in positive control and lack of non-specific transgene
activation, however it may miss the activity of elements with weak
enhancer action, in which case Krt8 may represent a better choice
but may require the analysis of larger groups of embryos to
determine enhancer specificity.
Validating Computational Prediction for Muscle-Specific
Enhancers
The genomic footprint of transcriptional regulation consists of
modules of transcription factor binding sites (TFBS) residing
Table 1. Evaluating promoter and enhancer specificity to determine optimum transgenic construc configuration for enhancer
characterization.
b-globin (none) c-cry (eye)
Transgenic
Efficiency Eye/Skin Muscle/Kidney Other
Transgenic
Efficiency Eye/Skin Muscle/Kidney Other
Promoter Only 0/173 0 0 0 43/56 (76%) 100% 0 0
IRX3 KE 27/101 (27%) 0 56% 44% 219/282 (77%) 60% 40% 0
Dystophin ME 97/202 (48%) 0 98% 2% 76/179 (42%) 47% 53% 0
MyoD ME 93/133 (70%) 0 100% 0 169/181 (93%) 4% 96% 0
Irx3 (eye) Krt8 (skin)
Transgenic Efficiency Eye/Skin Muscle/Kidney Other Transgenic Efficiency Eye/Skin Muscle/Kidney Other
Promoter Only 25/138 (18%) 60% 28% 22% 167/211 (79%) 80% 3% 17%
IRX3 KE 47/97 (48%) 30% 60% 10% 161/214 (75%) 60% 24% 16%
Dystophin ME 80/199 (40%) 2% 96% 2% 156/177 (88%) 25% 69% 6%
MyoD ME 87/173 (50%) 2% 98% 0 167/178 (93%) 9% 89% 2%
Hsp68 (none)
Transgenic Efficiency Eye/Skin Muscle/Kidney Other
Promoter Only 86/110 (78%) 20% 56% 24%
IRX3 KE 79/99 (79%) 21% 49% 30%
Dystophin ME 162/182 (89%) 10% 75% 15%
MyoD ME 205/240 (85%) 12% 78% 10%
doi:10.1371/journal.pone.0068548.t001
Transgenic Xenopus
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within gene regulatory elements. Tissue-specific regulatory
elements are thought to harbor similar TFBS modules character-
istic of particular transcription factors (TFs) involved in gene
regulatory programs specific to that tissue. From the computa-
tional perspective, the presence of similar TFBS combinations in a
set of sequences necessitates the use of pattern search approaches
capable of extracting the sets of TFBS that are characteristic to an
input set of co-functional regulatory elements. In practice, large
sets of tissue-specific regulatory elements are rarely available.
Genome-wide gene expression experiments (gene expression
arrays and RNA-Seq studies) usually retrieve sets of co-expressed
genes, each with a locus full of many potential regulatory elements
and only few that are active specifically in the tissue of interest.
This creates a computational challenge when a set of putative
regulatory elements should be extracted from a set of loci of co-
expressed genes. Then, these sets of elements (one per locus) would
be combined and compared to identify a small number of elements
in each locus that share their composition of TFBS across the set of
gene loci, arguing for the functional similarity within this set of
Figure 2. Characterizing minimal promoters for their ability to drive enhancer expression in a robust and reproducible manner.
Three evolutionary conserved and previously characterized enhancers were examined as positive controls (A), in combination with 5 minimal
promoters that have been previously employed in transgenic experiments in mice, zebrafish and frog (B). Frog embryos were examined for eye,
kidney and muscle expression between stages 30–45 of embryonic development (C) in all enhancer-promoter combinations (D–G).
doi:10.1371/journal.pone.0068548.g002
Transgenic Xenopus
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elements that corresponds to the function of genes and is reflective
of tissue-specific enhancer function of these elements.
We have previously developed a computational approach called
Enhancer Identification or EI [26] that predicts tissue-specific
enhancers and their characteristic TFBS modules from a set of
genes co-expressed in a particular tissue. We applied EI to a set of
300 genes determined to be highly expressed in skeletal muscle
according to the GNF Novartis Atlas of gene expression in mouse
tissues [27]. This method detected a set of 190 putative skeletal
muscle enhancers (SME) within the loci of these transcripts, with
56% of them residing distal to the nearest promoter region (Table
S2). A follow up analysis of TFBS combinations shared by the
predicted SMEs revealed a pronounced presence of MEF2, SRF,
MyoD, Myogenin, and UBP1 (aka LBP1) TFBSs, with MEF2 sites
being present in 40% of the predicted SMEs. While the first four of
these TFs (including MEF2) have been shown to play key roles
during muscle development (Li et al. 2005; Naya and Olson 1999),
little is known about UBP1 except that it regulates extra-
embryonic angiogenesis (Parekh et al. 2004).
The top 20 SME predictions were examined in frog enhancer
assays, using both the c-cry and Krt8 Tol2 transgenic constructs
described above. Eleven or 55% of these predicted elements
showed tissue specific activity. Six elements displayed muscle-
enhancer activity in combination with both the c-cry and the Krt8
promoter (Fig. 3), and 3 additional elements were weakly positive
only with the Krt8 promoter (Table 2; Fig. S1A–C). Two other
elements had enhancer activity in tissues other than muscle, one
displaying a neuronal (SME12) and the other a skin pattern
(SME14; Table 2; Fig. S1D–E); only one of these elements was
positive in combination with Krt8 promoter; SME12 did not come
up positive for hindbrain in combination with the Krt8 promoter
most likely because the skin expression masked the underlying
hindbrain expression observed with c-cry. Three of the 9
confirmed SMEs were intronic, four were positioned within
59UTRs, one was intergenic and one was within a promoter
region (Table 2; Fig. 3A–F). All genes associated with the SMEs
confirmed in both the c-cry and Krt8 promoter constructs have
been previously shown to function in skeletal muscle and included:
adenylosuccinate synthase like 1 (Adssl1) [28], troponin C type 2
(Tnnc2) [29], phosphoglycerate mutase 2 (Pgam2) [30], muscle
creatine kinase (Ckm) [31], myozenin 1 (Myoz1) [32] and
Leiomodin 3 (Lmod3) [33]. Only one of the three elements
confirmed with the Krt8 promoter only was associated with a gene
previously shown to function in skeletal muscle: integrin beta 1
binding protein 2 or melucin (Itgb1bp2) [34], while the other genes
Solute carrier family 25-member 25 (Slc25A25) and fat storage
inducing transmembrane protein 1 (Fitm1) have not yet been
examined in skeletal muscle. All SMEs except SME8 correspond
to novel muscle specific regulatory elements; SME8 overlaps with
Figure 3. Validating computational predictions for muscle enhancers in Xenopus trangenics. Predicted SMEs corresponded to
evolutionary conserved elements proximal or distal to genes known to function in skeletal muscle (A-F). Six SMEs consistently expressed in skeletal
muscle, in addition to eye (A9–F9). Genomic regions are color coded as follows: exons (blue); UTRs (yellow); repeats (green); conserved noncoding
sequences (red); predicted SMEs are shaded in purple.
doi:10.1371/journal.pone.0068548.g003
Transgenic Xenopus
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Table 2. The top 20 SME computational predictions were examined in combination with the c-cry and the Krt8 promoter.
-cry-promoter constructs
Genomic Adjacent # Embryos Transgenic Expression % Tissue Enhancer
ID
Element
Location (mm9) Context Gene Score Injected Survived Total Eye Muscle Other Specificity Function
SME1 chr2:32302688–
32303221
intron Slc25a25 23.495 300 248 232 225 5 0 0 No
SME2 chr12:113856421–
113856740
intergenic Adssl1 18.945 380 212 194 63 130 6 67 Muscle
SME3 chr2:164604395–
164604716
intron Tnnc2 13.504 610 357 305 227 77 9 25 Muscle
SME4 chr11:5703692–
5703983
UTR5 Pgam2 13.226 430 231 163 103 58 2 35 Muscle
SME5 chr6:14705247–
14705528
UTR5 Ppp1r3a 11.861 260 198 148 140 8 0 0 No
SME6 chr8:126408666–
126408924
intergenic Acta1 11.434 1080 353 220 205 3 12 0 No
SME7 chr5:130347257–
130347469
intron Phkg1 10.212 170 120 93 93 0 0 0 No
SME8 chr7:19995139–
19995384
promoter Ckm 9.821 400 254 235 18 216 1 92 Muscle
SME9 chr14:27707593–
27708097
UTR5 Asb14 9.493 200 125 97 97 0 0 0 No
SME10 chr14:56194193–
56194518
UTR5 Fitm1 8.859 300 155 97 89 8 0 0 No
SME11 chrX:98644054–
98644511
UTR5 Itgb1bp2 8.103 330 253 146 139 7 0 0 No
SME12* chr10:17515705–
17516036
UTR5 Txlnb 8.057 310 188 96 56 0 38 39 Hindbrain
SME13 chrX:154136273–
154136451
promoter Smpx 7.602 100 82 69 69 0 0 0 No
SME14* chr3:151927751–
151928151
intron Nexn 7.519 375 266 173 129 0 44 25 Skin
SME15 chr3:102877718–
102878018
UTR5 Ampd1 7.469 300 170 51 51 0 0 0 No
SME16 chr14:21470944–
21471529
intron Myoz1 7.175 670 343 213 123 125 25 58 Muscle
SME17 chr1:164569192–
164569394
UTR5 Myoc 7.08 500 237 134 131 0 3 0 No
SME18 chr6:97202653–
97202980
UTR5 Lmod3 6.786 300 250 157 99 58 1 37 Muscle
SME19 chr6:29381445–
29381811
promoter Flnc 6.756 400 140 104 101 2 3 0 No
SME20 chr9:121686568–
121686893
UTR5 Kbtbd5 6.461 300 156 97 95 0 2 0 No
Krt8-promoter constructs
Genomic Adjacent # Embryos Transgenic Expression % Tissue Enhancer
ID Element
Location (mm9)
Context Gene Score Injected Survived Total Eye Muscle Other Specificity Function
SME1 chr2:32302688–
32303221
intron Slc25a25 23.495 770 445 312 197 100 15 32 Muscle
SME2 chr12:113856421–
113856740
intergenic Adssl1 18.945 560 149 102 46 72 0 70 Muscle
SME3 chr2:164604395–
164604716
intron Tnnc2 13.504 490 177 99 59 36 4 35 Muscle
SME4 chr11:5703692–
5703983
UTR5 Pgam2 13.226 430 231 163 103 58 2 35 Muscle
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the 206-bp MCK enhancer that has been previously characterized
in muscle cell lines and in transgenic mice [35].
Mef2 and MyoD TFBS are Critical for SME8 and SME16
Function
To further explore if a specific pattern of TFBS may be required
for driving skeletal muscle specific expression, we mapped all
TFBS conserved from mouse to human onto the 20 predicted
SMEs. Using the cluster analysis function of the MultiTF tool
(http://multitf.dcode.org/), we found that 9/20 SMEs included
clusters with at least one Mef2 and one MyoD sites within
,200 bp regions. All 6 SMEs validated had these features as well
as 1/3 of the Krt8-only validated elements (SME11). Of all
predicted SMEs, two elements that scored negative in the
transgenic assay, (SME6/20) had this feature (Fig. 4). To
functionally link the Mef2 and MyoD target sites to muscle-
specific expression, we created two new constructs that included
both the kidney enhancer and the muscle enhancers SME8 or
SME16 within the Tol2-c-cry vector (Fig. 5A). SME8 had a cluster
of 1 Mef2 and 2 MyoD within 100 bp, and one additional Mef2
site .100 bp away (Fig. 5B). SME16 had only one cluster of a
Mef2 and a MyoD predicted site present within a 100 bp DNA
fragment (Fig. 5H). Next, we systematically deleted the Mef2, the
MyoD or both the Mef2/MyoD sites present within the 100 bp
region in SME8 (Fig. 5C–F) and SME16 (Fig. 5I–L) and examined
transgenic frequency and expression intensity in both kidney and
skeletal muscle (Table S3).
Enhancer proximity to the promoter influenced the ‘tissue-
specificity’ activation level, such that the largest number of
transgenic embryos expressing unaltered SME8 or SME16
constructs had muscle expression: 100% for SME8 (73% muscle
only; 27% muscle and kidney; 0% kidney only) and 74% for
SME16 (26% muscle only; 38% muscle and kidney; 5% kidney
only). All deletion constructs had a decrease in the % of transgenic
animals that expressed in the muscle, as well as a decrease in the
expression intensity (Fig. 5G). As the muscle enhancer activity
‘weakened’ due to TFBS deletions, the kidney enhancer activity
increased. When either the Mef2 or MyoD sites were deleted in
SME8 the percentage of transgenic embryos expressing exclusively
in skeletal muscle tissue decreased by,45% and the percentage of
Table 2. Cont.
-cry-promoter constructs
Genomic Adjacent # Embryos Transgenic Expression % Tissue Enhancer
ID
Element
Location (mm9) Context Gene Score Injected Survived Total Eye Muscle Other Specificity Function
SME5 chr6:14705247–
14705528
UTR5 Ppp1r3a 11.861 420 153 87 67 20 0 23 No
SME6 chr8:126408666–
126408924
intergenic Acta1 11.434 275 202 147 147 0 2 0 No
SME7 chr5:130347257–
130347469
intron Phkg1 10.212 420 225 135 99 15 21 11 No
SME8 chr7:19995139–
19995384
promoter Ckm 9.821 840 456 353 105 230 18 65 Muscle
SME9 chr14:27707593–
27708097
UTR5 Asb14 9.493 420 139 104 76 21 7 20 No
SME10 chr14:56194193–
56194518
UTR5 Fitm1 8.859 420 263 79 40 36 3 45 Muscle
SME11 chrX:98644054–
98644511
UTR5 Itgb1bp2 8.103 420 188 161 76 73 12 45 Muscle
SME12 chr10:17515705–
17516036
UTR5 Txlnb 8.057 280 184 149 146 3 0 2 No
SME13 chrX:154136273–
154136451
promoter Smpx 7.602 240 125 74 72 2 0 2.7 No
SME14* chr3:151927751–
151928151
intron Nexn 7.519 240 150 110 76 2 32 42 Skin
SME15 chr3:102877718–
102878018
UTR5 Ampd1 7.469 100 62 53 51 1 1 1.8 No
SME16 chr14:21470944–
21471529
intron Myoz1 7.175 100 38 28 16 11 1 39 Muscle
SME17 chr1:164569192–
164569394
UTR5 Myoc 7.08 100 57 134 18 0 0 0 No
SME18 chr6:97202653–
97202980
UTR5 Lmod3 6.786 160 44 34 15 19 0 56 Muscle
SME19 chr6:29381445–
29381811
promoter Flnc 6.756 100 40 104 23 0 0 2 No
SME20 chr9:121686568–
121686893
UTR5 Kbtbd5 6.461 100 52 37 35 0 1 0 No
*elements show enhancer activity in a tissue other than the predicted tissue.
doi:10.1371/journal.pone.0068548.t002
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transgenic expressing in the kidney increased by ,50% (Fig. 5D–
E). Deleting the 73 bp region containing a cluster of 1 Mef2 and
2 MyoD sites in SME8 dramatically reduced the number and
intensity of the muscle expression to 18% and the kidney
expression increased to 39% (Fig. 5F). The remaining embryos
that expressed in the muscle, had an average expression intensity
85% below the intensity observed in the intact SME8 transgenic
embryos (Fig. 5G).
For SME16, deleting the Mef2 site reduced the number of
muscle expressing embryos by 97% and increased the number of
kidney expressing embryos 7-fold (Fig. 5J). Deleting MyoD had a
less dramatic effect on the overall % of transgenic embryos
expressing in the muscle, and the expression intensity was
unaffected (Fig. 5K, M). Deleting both the Mef2 and MyoD sites
in SME16 reduced the muscle transgenics to 13%, and the muscle
expression was half of that detected for the unaltered SME16
construct (Fig. 5L, M). In addition to observing a reduction in the
transgenic frequency, all deletion constructs but SME16_DMyoD
had significantly less intense muscle expression relative to the
wildtype constructs, suggesting that these sites are required for
robust transgene activation. As the muscle expression dimmed, the
kidney expression increased, suggesting that the enhancers are
slightly competing with each other and that the enhancer closer to
the promoter is favored. While enhancer competition has not yet
been thoroughly investigated in vertebrates, it has been docu-
mented for many loci in Drosophila [36], and promoter
competition has been observed in humans [37,38]. However, the
enhancer blocking activity of the proximal enhancer diminished
with loss in activation potency due to Mef2 and MyoD mutations.
Discussion
In this study we aimed to develop a high throughput transgenic
system for validating tissue-specific enhancer function in vivo, in
real time, in a vertebrate organism, and overcome some of the
limitations posed by current technologies in the mouse and
zebrafish model organisms. The optimization focused on: trans-
genic efficiency, promoter sensitivity and specificity, as well as
reporter stability and expression intensity to generate a universal
transgenic construct that is silent or ‘off’ in the absence of a tissue
specific regulatory element, yet is capable of activating the reporter
gene in a highly specific manner even when combined with a
‘weak’ tissue-specific enhancer. Initially we focused on transgenic
methods in Xenopus using viability and transgenic efficiency as a
metric. Side by side comparisons of nuclear gene transfer (REMI)
and two transposon-mediated transgenic systems: PiggyBAC and
Tol2 found both transposable element systems to be superior in
embryo viability relative to REMI; however Tol2 yielded the
largest percentage of transgenic embryos among the 3 groups
(Fig. 1B). Among reporter genes, we chose to examine a family of
red fluorescent proteins that are near the infrared range, to
identify the brightest, most stable with least associated auto-
fluorescence in Xenopus. We found Katushka and subsequently the
monomer mKate2 to be the brightest and with the least non-
specific signal generated by the Xenopus tissue (Fig. 1A).
Using a previously described enhancer prediction method we
evaluated whether: 1) this in silico approach can reliably distinguish
enhancers active during vertebrate skeletal muscle development
and differentiation and 2) whether Xenopus transgenesis can be
efficiently employed to validate tissue specific enhancers. Among
the 20 tested elements from the 190 predictions across the mouse
genome, 9 showed muscle-specific activity either in combination
with c-crystalin, keratin-8 or both promoters, 2 predicted
enhancers exhibited expression patterns in a tissue other than
the predicted site (skin and brain), and the remainder 9 elements
did not have a detectable enhancer activity in transgenic Xenopus,
examined up to stage 45. These results suggest that in vivo
validation of muscle-specific enhancer predictions in transgenic
frogs had a success rate of 45%. Furthermore, it is important to
note that the computation approach employed represents a great
improvement upon using evolutionarily conservation as the only
selection criteria for candidate tissue-specific enhancers. Fig. 3A–F
depicts the human/mouse conservation profile for the genetic loci
Figure 4. TFBS analysis. Top 20 predicted SMEs were examined for the presence of Mef2 and MyoD clusters. We found clusters of .2 Mef2/MyoD
sites over regions .200 bp in all 6 SMEs shown to drive muscle expression in combination with c-cry promoter (red) and 1/3 of the additional 3
enhancers that were found to drive muscle expression in combination with krt8 promoter only (orange). Two of the negative elements also displayed
this cluster (SME6/SME20), but none of the enhancers found to express in tissues other than muscle (green).
doi:10.1371/journal.pone.0068548.g004
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corresponding to the neighboring gene of the validated SMEs.
Each locus has a minimum of 3 conserved noncoding sequences
and as many as 23 such elements, therefore the enhancer
identification method significantly enriched for elements with
tissue-specific activity and represents an important prioritization
tool for determining which elements should be validated in vivo, in
costly, laborious functional assays.
More recently there have been new computational classifiers
that can further improve the predictive power of tissue specific
enhancers [39]. One recent report used a training set of validated
cardiac enhancers to predict cardiac enhancers a priori across the
human genome, and cross-validation in Zebrafish demonstrated
that 62% of the predictions corresponded to heart enhancers [39].
A future goal of our work is to apply these 9 newly described
skeletal muscle enhancers along with others described in the
literature to refine skeletal muscle predictors and improve
reliability. One important distinction is worth noting is the
homogeneity of expression we observed among the validated
enhancers in Xenopus, using the Tol2-construct we engineered. In
general, most previous reports of validated tissue-specific enhancer
predictions in zebrafish or mouse transgenics, the predicted tissue
is not generally the only positive tissue associated with the
confirmed enhancers, nor is the pattern of expression always the
same. For example, among the cardiac enhancers that were
validated in mice [39], some enhancers gave rise to distinct spatial
domains of expression outside the heart field. This spatial
heterogeneity could be the result of several factors: 1) position
effect where the transgene is influenced by the genomic context of
the site of DNA integration; 2) promoter permissiveness where
certain ‘minimal promoters’ are prone to activation bias, i.e. they
sporadically turn on in a certain cell lineages, or 3) the modular
nature of transcriptional regulatory elements, each of which
corresponds to a different array of transcription factor binding sites
that cumulatively contribute to the spatial specificity of an
element. What the computation method recognizes as a tissue
specific enhancer is a combination of TFBSs that together
correspond to a shared character of the DNA elements examined.
However, the predicted elements may include other unrecognized
features that also contribute to the modular function of these
elements. Nonetheless, it is worth highlighting that 100% of the
skeletal muscle enhancers validated in the Xenopus transgenic
strategy described here had an indistinguishable expression
pattern, namely in the fast muscle fibers that are oriented in
highly organized chevrons along the notochord in the Xenopus laevis
tadpole. Also, most of the expression was in the trunk region and
up to somite ,25, suggesting that the expression of these
regulatory elements marks a subset of muscle cells which does
not extend to the slow muscle fibers that develop in the posterior-
to-anterior direction and emerge at the 30 somite stage [40]. Such
high cellular specificity in enhancer activity can now be further
explored to determine the underlining sequence signatures
responsible for this activity. Future studies using training sets that
correspond to highly specialized subsets of enhancers will likely
uncover a different collection of predicted enhancers, with distinct
spatial specificities in a given tissue.
Earlier work by Wasserman and Fickett employed linear and
logistic regression to computationally predict DNA regions specific
to genes expressed in muscle [41] based on the presence of position
weight matrices defined for a set of muscle-specific transcription
factors including: Mef2, Myf, Sp1, SRF, and Tef transcription
factors. Whereas these studies predicted regions with cohorts of
these muscle-specific TFBS in the promoters of genes known to be
expressed in muscle, the predicted elements were correlative, and
were not functionally validated to confirm first the enhancer
activity and second the contribution of individual TFBS to the
enhancer activity and tissue specificity. The Xenopus transgenic
assay however, can now facilitate the systematic mutagenesis of
these sequence signatures to determine which sites are essential or
additive in nature. Using the principle that 1 or more of these
TFBS contribute to the ‘strength’ and ‘tissue-specificity’ of these
elements, we deleted MyoD and Mef2 TFBS from two of the
validated enhancers and showed that in both cases removing the
individual TFBS or the whole combinatorial module diminished
the enhancer activity by decreasing expression intensity and tissue-
specific transgenic efficiency.
This study identified novel skeletal muscle enhancers likely to
play critical roles during myogenic differentiation and muscle
physiology. Our computational predictions of mammalian en-
hancers that have potential tissue specific activity combined with
the transgenic tools we developed in Xenopus are likely to facilitate
the validation and characterization of tissue-specific elements. The
in vivo validation represents a new and cost effective in vivo
enhancer screening tool which can help elucidate the mechanisms
of gene regulation with the ultimate goal of determining the
genetic variation that contributes to normal physiology and
disease.
Materials and Methods
Transgenesis
Restriction enzyme mediated transgenesis by sperm nuclear
transfer was performed as previously described [19,42]. Briefly,
4 mL of gel purified insert DNA (150–250 ng/mL) was mixed at
room temperature (RT) with 5 mL sperm nuclei (1.256108 nuclei/
mL), incubated for 5 min and diluted with 23 mL of sperm dilution
buffer, 4 mL MgCl2 (50 mM) and 0.5 mL NotI restriction enzyme,
after a 10 min incubation at RT the mixture was transferred to a
chilled aluminum block. De-jellied fresh eggs were washed 5x with
chilled 1X MMR, transferred to 0.2X MMR +4% Ficoll in
agarose injection dishes, and injected with the sperm nuclei
suspension. Injected embryos were transferred to new dishes with
fresh 0.2X MMR +4% Ficoll +100 mg/mL Gentamycin and were
incubated at 15uC for 12–16 hours, after which healthy embryos
are transferred to 0.2X MMR +100 mg/mL Gentamycin and
monitored for gene expression using fluorescence. PiggyBAC
transgenics were generated as previously described [14]. Tol2
tranposase RNA was prepared using in vitro transcription of Xba I-
digested pT3TS/Tol2 plasmid (a gift from Dr. S.Ekker) [43] using
T3 Ambion mMessage Machine kit. Transgene DNA was
prepared using Qiagen midi-prep kits and stored in RNase-free
water at 4uC. RNA and DNA were mixed 1:1 and 125–150 pg of
Figure 5. Mef2C/MyoD sites are essential for SME8/16 muscle specific expression. Tol2 constructs containing tandem kidney (KE) and
muscle (SME) enhancers in front of c-cry promoter (A) were systematically mutated to remove the predicted Mef2 and MyoD sites (B, H), and
compared to the ‘wildtype’ construct in transgenic efficiency and tissue specificity (C, H), as well as expression intensity (G, M). Mutating either Mef2C
or MyoD sites reduced the number of embryos expressing in muscle, as well as reduced the expression intensity (D-F; I-K; G, M). [*p-value,0.05; **p-
value ,0.001].
doi:10.1371/journal.pone.0068548.g005
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DNA and RNA each were injected in a 3 nL volume using a
PicoSpritzer III (Parker Instrumentation). Embryos were injected
near the sperm entry point in 2.5% ficoll in 1/3 MR at 12uC. Post
injection the embryos are transferred to agarose coated dishes
containing 1/3 MR +50 mg/mL Gentamycin at 12uC up to 16
cell stage, then transferred to 15uC-RT and scored for fluores-
cence. Tadpoles were scored and photographed between stages 38
and 40. Each tadpole was examined for expression sites on both
sides. Photos were taken on a Leica MZ16FA fluorescence
dissecting scope using Image Pro Plus software, and bright field
and fluorescent images were superimposed using either GIMP or
Adobe PhotoShop. Because images were not pseudocolored using
grayscale intensity mapping, some autofluorescence was observed
in the gut of overexposed embryos, particularly for constructs that
had weaker expression like the c-cry promoter only construct
(Fig. 2D).
Reporter Genes
Katushka or TurboFP635 (Evrogen Cat No. FP721) is a
26 KDa dimeric far-red protein from sea anemone Entacmaea
quadricolor with fast maturity and high photostability [13].
mKate2 (Evrogen Cat. No. FP181) is a similar far-red protein
with a few slight differences: it is a monomer and it is documented
to be ,3X brighter than Katushka [44].
Quantifying Fluorescence
Quantification of skeletal muscle transgene expression was
performed using NIH ImageJ. The skeletal muscle region along
the back and tail of the transgenic tadpoles was analyzed for mean
red fluorescent intensity. Measurements were performed on four
tadpoles for each transgene then normalized to the average
intensity obtained from the un-mutated SME constructs. P-values
were obtained using paired T-tests.
Cloning
Ef1A promoter+GFP in the Tol2 pT2KXIG vector (gift from
Dr. K. Kawakami) were replaced by CMV-Katuskha (Evrogen),
and subsequently the CMV promoter was excised and replaced by
Krt8 (pKrt8eGFP-tol2; gift from Dr. V. Korzh), c-cry, b-globin (b-
globin-eGFP; gift from Dr. S. Ekker), Hsp68 (pHsp68-LacZ; gift
from Dr. D. Mortlock) and Irx3 (pIrx-eGFP; gift from Dr. J.
Skarmeta) promoters. KE was excised from pIrx-KE-eGFPVector
(gift from Dr. J. Skarmeta), all predicted SMEs and the two
positive control MEs were PCR amplified from mouse DNA and
cloned in the EcoR1 site of pT2gK2 (JN418198) vector. All
constructs were sequence verified.
Accession Numbers
Vector-pT2gK2 (JN418198); SME2 (JN418199); SME3
(JN418200); SME4 (JN418201); SME8 (JN418202); SME12
(JN418203); SME14 (JN418204); SME16 (JN418205); SME18
(JN418206); KE (JN418207); SME8-DMef2 (JN613839); SME8-
D2XMyoD (JN613840); SME8-D147-220 (JN613841); SME16-
DMef2 (JN613842); SME16-DMyoD (JN613843); SME16-D220-
290 (JN613844).
Supporting Information
Figure S1 SME1 (A), SME10 (B), SME11 (C) showed muscle
expression in combination with Krt8 but not c-cry promoter
(yellow arrow). SME12 showed highly reproducible transgenic
expression in the hindbrain (D; green arrow), and SME 14 in the
skin (E; green arrow).
(TIF)
Table S1 Comparing survival and transgenic efficiency among 3
Xenopus transgenesis methods: nuclear transfer, PiggyBAC trans-
poson mediate and Tol2 transposon mediated transgenesis. For
each method 250 embryos were injected in 4 different experi-
ments, and the number of surviving and transgenic embryos were
recorded. A paired T-test was used to determine if there was a
significant difference between the surviving and transgenics. For
each method the expression intensity was evaluated in the
transgenic embryos, and was classified as ‘ubiquitous’ (uniformly
over the entire embryo), ‘low chimera’ (a small subset of the
embryo had expression, or ‘high chimera’ (.50% of the embryo
had expression).
(XLS)
Table S2 Muscle Enhancer Predictions generated by the EI
method.
(XLSX)
Table S3 Tissue specific expression is compared among
transgenic embryos carrying mutations in Mef2 and MyoD sites
of SME8 and SME16 muscle enhancers. The number of embryos
with specific expression patterns are indicated, the percentages are
graphed in Figure 5.
(XLSX)
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